For research use only. Not for therapeutic Use.
Donanemab（Cat No.:I042079）is an investigational monoclonal antibody designed to target and clear amyloid plaques in the brain, which are associated with Alzheimer’s disease. By binding to a specific form of amyloid-beta, donanemab aims to reduce plaque buildup and potentially slow the progression of cognitive decline in Alzheimer’s patients. It is being studied in clinical trials to assess its safety, efficacy, and ability to improve cognitive function. Donanemab is part of a broader effort to develop therapies that modify the underlying disease pathology rather than just manage symptoms of Alzheimer’s disease.
| Catalog Number | I042079 |
| CAS Number | 1931944-80-7 |
| Purity | ≥95% |
